<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018117</url>
  </required_header>
  <id_info>
    <org_study_id>2018-12-11682</org_study_id>
    <secondary_id>R01AG067073-01A1</secondary_id>
    <nct_id>NCT05018117</nct_id>
  </id_info>
  <brief_title>Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex</brief_title>
  <official_title>Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Berkeley</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nicotine enhances auditory-cognitive function because it mimics the brain's system for&#xD;
      &quot;paying attention&quot; to important sounds amid distractions (for example, understanding speech&#xD;
      in a noisy environment). In part, nicotine does this by activating inhibitory neurons in the&#xD;
      auditory cortex. Since age-related hearing deficits result, in part, from the loss of&#xD;
      inhibitory neurons in auditory cortex, this project will determine whether nicotine's effects&#xD;
      can compensate for reduced inhibition in the aging auditory cortex and thereby restore&#xD;
      auditory function.&#xD;
&#xD;
      The investigators will use functional magnetic resonance imaging (fMRI) to measure the&#xD;
      selectivity of responses in auditory cortex to tones of various frequencies. The&#xD;
      investigators will measure the effects of nicotine (administered as chewing gum) and aging on&#xD;
      these fMRI response properties. The investigators hypothesize that frequency selectivity will&#xD;
      decrease with aging and increase following nicotine administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Nicotine (6 mg, polacrilex gum) and placebo will be administered to each participant in separate sessions in a within-subject double-blind randomized crossover design. Subjects will be in either a young (18-28 years) or old (60-85 years) group.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency tuning of excitatory auditory fMRI cortical responses</measure>
    <time_frame>Functional MRI recordings will begin approximately 30 minutes after oral administration of polacrilex or placebo gum and will continue for up to two hours.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) responses to pure tone stimuli ranging from 88-8000 Hz will be recorded. For each voxel in objectively identified auditory cortical area, a tuning curve model will be fit to the data. One of the parameters of this model is the width of frequency tuning of excitatory responses, and this is the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency tuning of inhibitory auditory fMRI cortical responses</measure>
    <time_frame>Functional MRI recordings will begin approximately 30 minutes after oral administration of polacrilex or placebo gum and will continue for up to two hours.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) responses to pure tone stimuli ranging from 88-8000 Hz will be recorded. For each voxel in objectively identified auditory cortical area, a tuning curve model will be fit to the data. One of the parameters of this model is the width of frequency tuning of inhibitory responses, and this is Outcome 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of excitatory auditory fMRI cortical responses</measure>
    <time_frame>Functional MRI recordings will begin approximately 30 minutes after oral administration of polacrilex or placebo gum and will continue for up to two hours.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) responses to pure tone stimuli ranging from 88-8000 Hz will be recorded. For each voxel in objectively identified auditory cortical area, a tuning curve model will be fit to the data. One of the parameters of this model is the amplitude of excitatory responses, and this is Outcome 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of inhibitory auditory fMRI cortical responses</measure>
    <time_frame>Functional MRI recordings will begin approximately 30 minutes after oral administration of polacrilex or placebo gum and will continue for up to two hours.</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) responses to pure tone stimuli ranging from 88-8000 Hz will be recorded. For each voxel in objectively identified auditory cortical area, a tuning curve model will be fit to the data. One of the parameters of this model is the amplitude of inhibitory responses, and this is Outcome 4.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Young (18-28 years) participants - nicotine gum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg nicotine gum, one time before fMRI measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old (60-85 years) participants - nicotine gum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg nicotine gum, one time before fMRI measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young (18-28 years) participants - placebo gum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo gum, one time before fMRI measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old (60-85 years) participants - placebo gum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo gum, one time before fMRI measurements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <description>The effects of over-the-counter nicotine gum will be compared to a placebo gum</description>
    <arm_group_label>Old (60-85 years) participants - nicotine gum</arm_group_label>
    <arm_group_label>Young (18-28 years) participants - nicotine gum</arm_group_label>
    <other_name>polacrilex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo gum</intervention_name>
    <description>The effects of over-the-counter nicotine gum will be compared to a placebo gum</description>
    <arm_group_label>Old (60-85 years) participants - placebo gum</arm_group_label>
    <arm_group_label>Young (18-28 years) participants - placebo gum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking&#xD;
             dependency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  deafness or excessive hearing loss&#xD;
&#xD;
          -  smokers with a score between 3 and 10 on the Fagerström index of smoking dependency&#xD;
&#xD;
          -  history of psychiatric illness, neurological disorders, diabetes mellitus, renal&#xD;
             failure, or cardiovascular disease&#xD;
&#xD;
          -  regular use of prescription medications (excluding oral contraceptives)&#xD;
&#xD;
          -  drug dependency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Silver, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Berkeley</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael A Silver, PhD</last_name>
    <phone>5106423130</phone>
    <email>masilver@berkeley.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Berkeley</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael A Silver, PhD</last_name>
      <phone>510-642-3130</phone>
      <email>masilver@berkeley.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>acetylcholine</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

